Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Disc Medicine, Inc. (NASDAQ:IRON) Chief Executive Officer John D Quisel, sold 5,200 shares of common stock on July 3, 2025, at prices ranging from $55.00 to $55.26, for a total value of $286,454. The transaction occurred with the stock trading near $53, giving the company a market capitalization of $1.84 billion. According to InvestingPro data, the stock has shown significant volatility with a beta of 2.5.
On the same day, Quisel also exercised options to acquire 5,200 shares of Disc Medicine common stock at a price of $9.86, for a total value of $51,272. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. InvestingPro analysis shows the company maintains a GOOD overall financial health score, with analysts setting price targets ranging from $75 to $132.
Following the sale, Quisel directly owns 161,828 shares of Disc Medicine. For deeper insights into insider trading patterns and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks including IRON.
In other recent news, Disc Medicine has been making significant strides, particularly with its drug bitopertin. H.C. Wainwright reiterated its Buy rating with a price target of $118, citing positive data from the HELIOS study for bitopertin in treating erythropoietic protoporphyria (EPP). BMO Capital also maintained its Outperform rating with a $120 price target, noting the company’s progress in its pipeline and the bitopertin NDA submission, which remains on track for the second half of 2025. Morgan Stanley (NYSE:MS) initiated coverage with an Overweight rating and an $85 price target, forecasting a 2026 launch for bitopertin and highlighting the potential of DISC-0974 in anemia treatments.
The company’s shareholders recently voted on executive pay and board members, electing three Class II directors to serve until 2028. Additionally, the appointment of Ernst & Young LLP as the independent auditor for 2025 was ratified. Disc Medicine continues to advance its pipeline, with H.C. Wainwright emphasizing the drug’s potential for accelerated approval. Meanwhile, BMO Capital highlighted the company’s efforts in commercialization strategies, including patient identification and payer engagement. These developments indicate a continued focus on advancing Disc Medicine’s therapeutic offerings and strategic plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.